PT Pyridam Farma Tbk Stocks

IDR 428Last Updated 27.01.2026

Issuer Rating

2/7

Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

IDR 289.91M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
IDR 428
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, antibiotics, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR –...

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks